Curtis Tyree

Corporate Officer/Principal presso ORGANOVO HOLDINGS, INC.

Health Technology

Profilo

Dr. Curtis Tyree is a Senior VP-Strategy & Business Development at Organovo Holdings, Inc. Dr. Tyree was previously employed as a Senior Vice President-Strategic Planning by HUYA Bioscience International LLC.

Posizioni attive di Curtis Tyree

Società	Posizione	Inizio
ORGANOVO HOLDINGS, INC.	Corporate Officer/Principal	18/02/2022

Tutte le posizioni attive di Curtis Tyree

Precedenti posizioni note di Curtis Tyree

Società	Posizione	Fine
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Curtis Tyree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Curtis Tyree

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ORGANOVO HOLDINGS, INC.	Health Technology

Aziende private	1
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Health Technology